Revenue
2019
2020
2021
2022
2023
2024
2025
CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.92B | $1.37B | $1.26B | $1.10B | $1.47B | $672.9M | $462.3M |
| Gross profit | — | — | $257.3M | $22.7M | −$79.2M | — | — |
| Operating expenses | $2.01B | $1.42B | $1.47B | $1.38B | $2.11B | $765.6M | $645.5M |
| Operating income | −$85.5M | −$45.7M | −$205.3M | −$286.7M | −$637.0M | −$92.7M | −$183.2M |
| EBITDAderived | −$83.8M | −$44.4M | −$202.8M | −$285.5M | −$636.8M | −$92.2M | −$182.6M |
| Net income | −$85.5M | −$43.0M | −$213.4M | −$339.6M | −$587.8M | −$136.4M | −$363.7M |
| Basic EPSper diluted share | — | — | -$0.44 | -$0.71 | -$1.42 | -$1.54 | -$4.14 |
| Diluted EPSper diluted share | — | — | -$0.44 | -$0.71 | -$1.42 | -$1.54 | -$4.14 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 17, 2026Form 4 · 10b5-1 | Reynoso Jamie L.CEO, Medicare Advantage | SellClass A Common Stock | 2.4K | $4.78 | $11.3K | 2.84M |
| Jun 16, 2026Form 4 · 10b5-1 | OLDAKOWSKI JOSEPH FRANKVP OF FINANCE AND CONTROLLER | SellClass A Common Stock | 12.1K | $4.86 | $58.8K | 299.1K |
| Jun 15, 2026Form 4 · 10b5-1 | Reynoso Jamie L.CEO, Medicare Advantage | SellClass A Common Stock | 6.3K | $4.61 | $29.3K | 2.84M |
| Jun 15, 2026Form 4 · 10b5-1 | Soares KarenChief Legal Officer | SellClass A Common Stock | 4.7K | $4.61 | $21.6K | 1.57M |
| Jun 11, 2026Form 4 · 10b5-1 | Reynoso Jamie L.CEO, Medicare Advantage | SellClass A Common Stock | 7.3K | $4.91 | $35.8K | 2.85M |